# A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

> **NCT05376150** · PHASE2 · COMPLETED · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 168 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** XEN1101 10 mg
- **DRUG:** XEN1101 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05376150
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-19
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-10-16
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05376150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05376150, "A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05376150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*